Feb 19, 2024
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
Feb 01, 2024
AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Jan 03, 2024
AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Feb 24, 2021
Amgen To Present At The Cowen 41st Annual Healthcare Conference
Feb 16, 2021
FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Feb 03, 2021
Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups
Feb 02, 2021
Amgen Reports Fourth Quarter And Full Year 2020 Financial Results
Jan 29, 2021
Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China
Jan 28, 2021
Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results
Jan 26, 2021
Amgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer
Jan 11, 2021
Amgen To Achieve Carbon Neutrality By 2027
Jan 11, 2021
Amgen To Achieve Carbon Neutrality By 2027
Dec 22, 2020
Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health
Dec 22, 2020
Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency
Dec 22, 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Dec 17, 2020
Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral
Dec 17, 2020
FDA Approves Amgen's RIABNI(TM) (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
Dec 16, 2020
Amgen To Transfer Listing Of Debt Securities To Nasdaq
Dec 16, 2020
Amgen Announces 10% Increase In 2021 First Quarter Dividend
Dec 16, 2020
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation